donor chimerism,
Showing 26 - 50 of 3,438
Immune Tolerance Trial in Palo Alto (Combined Deceased Donor Kidney and Hematopoietic Cell Transplants)
Enrolling by invitation
- Immune Tolerance
- Combined Deceased Donor Kidney and Hematopoietic Cell Transplants
-
Palo Alto, CaliforniaStanford University
May 6, 2022
Blood Disease Trial (TCRaß+/CD19+ depleted Hematopoietic stem cell (HSC) graft, CliniMACS® System)
Not yet recruiting
- Blood Disease
- TCRαβ+/CD19+ depleted Hematopoietic stem cell (HSC) graft
- CliniMACS® System
- (no location specified)
Jan 30, 2023
Idiopathic Aplastic Anemia, Severe Aplastic Anemia, Moderate Aplastic Anemia Requiring Transfusions Trial (HSCT Arm group)
Not yet recruiting
- Idiopathic Aplastic Anemia
- +2 more
- HSCT Arm group
- (no location specified)
Jun 10, 2022
Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia Trial in Pittsburgh (CD3/CD19 depleted leukocytes, CD45RA
Recruiting
- Sickle Cell Anemia
- +2 more
- CD3/CD19 depleted leukocytes
- +6 more
-
Pittsburgh, PennsylvaniaChildren's Hospital of Pittsburgh of UPMC
May 4, 2022
Severe Combined Immune Deficiency (SCID) Trial run by the National Institute of Allergy and Infectious Diseases (NIAID)
Enrolling by invitation
- Severe Combined Immune Deficiency (SCID)
- Sirolimus
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 24, 2022
Living Donor Kidney Transplantation Trial in Palo Alto, Chicago (Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs)
Recruiting
- Living Donor Kidney Transplantation
- Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
-
Palo Alto, California
- +1 more
May 6, 2022
MDS, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in Aachen, Düsseldorf, Jena (Venetoclax, Amsacrine,
Not yet recruiting
- Myelodysplastic Syndromes
- +2 more
- Venetoclax
- +4 more
-
Aachen, NRW, Germany
- +2 more
Mar 29, 2023
Multiple Sclerosis Trial (hematopoetic stem cell infusion)
Active, not recruiting
- Multiple Sclerosis
- hematopoetic stem cell infusion
- (no location specified)
Jul 15, 2022
Haplo-identical Transplants in Fanconi Disease
Not yet recruiting
- Fanconi Syndrome
- Blood sampling
- (no location specified)
Jun 6, 2023
Sickle Cell Disease Trial in Amsterdam (Engerix-B)
Recruiting
- Sickle Cell Disease
-
Amsterdam, NetherlandsAmsterdam Medical Centre
Jan 6, 2022
Graft Vs Host Disease Trial in New York (Cyclophosphamide, Abatacept, Tacrolimus)
Recruiting
- Graft Vs Host Disease
- Cyclophosphamide
- +2 more
-
New York, New YorkNYU Langone Health
Nov 10, 2022
AML, MDS, ALL, Adult Trial in Hackensack, New York (SOC + TSC-100, SOC + TSC-101, Control)
Recruiting
- AML
- +2 more
- SOC + TSC-100
- +2 more
-
Hackensack, New Jersey
- +1 more
Aug 11, 2022
Anemia, Sickle Cell Trial in New York (Siplizumab, Exchange Transfusion, Total Body Irradiation)
Recruiting
- Anemia, Sickle Cell
- Siplizumab
- +7 more
-
New York, New YorkColumbia University Irving Medical Center
Oct 9, 2023
Kidney Transplant Rejection Trial (MDR-102, Immunosuppressive Agents)
Not yet recruiting
- Kidney Transplant Rejection
- MDR-102
- Immunosuppressive Agents
- (no location specified)
Apr 4, 2022
Sickle Cell Disease Trial in Memphis (hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and
Recruiting
- Sickle Cell Disease
- hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus
- hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus
-
Memphis, TennesseeSt. Jude Children's Research Hospital
May 5, 2022
Intestinal Transplantation Trial in New York (Cell Therapy)
Recruiting
- Intestinal Transplantation
- Cell Therapy
-
New York, New YorkColumbia University Irving Medical Center/NYP
Dec 28, 2021
Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure Trial in Baltimore (Alemtuzumab, Fludarabine,
Recruiting
- Primary Immune Deficiency Disorder
- +2 more
- Alemtuzumab
- +6 more
-
Baltimore, MarylandJohns Hopkins University
Oct 20, 2022
Bone Marrow Failure Syndromes Trial in Philadelphia (MRD-BMT with Fludarabine-based RIC for Acquired AA, MRD-BMT with
Recruiting
- Bone Marrow Failure Syndromes
- MRD-BMT with Fludarabine-based RIC for Acquired AA
- +2 more
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
May 6, 2022
SIOD With CKD Stage 3 Through 5, Cystinosis With CKD Stage 3 Through 5, FSGS With CKD Stage 3 Through 5 Trial in Palo Alto
Not yet recruiting
- SIOD With CKD Stage 3 Through 5
- +3 more
- Cyclophosphamide 1200 mg/Kg
- +8 more
-
Palo Alto, CaliforniaLucile Packard Children's Hospital
Aug 17, 2022
Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders Trial in Bethesda,
Recruiting
- Lymphoproliferative Disorders
- +4 more
- Immunosuppression Only Conditioning
- +3 more
-
Bethesda, Maryland
- +1 more
Jan 25, 2023
Acute Myeloid Leukaemia (AML), MDS (MDS) Trial in Germany, Netherlands (Panobinostat)
Active, not recruiting
- Acute Myeloid Leukaemia (AML)
- Myelodysplastic Syndromes (MDS)
-
Stuttgart, Baden-Württemberg, Germany
- +18 more
Dec 13, 2021
Graft-versus-host Disease Trial in New York (Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention)
Active, not recruiting
- Graft-versus-host Disease
- Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
-
New York, New YorkNYU Langone Health
Aug 5, 2022
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia Trial in United States (drug, procedure, other, radiation)
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +10 more
- Busulfan
- +10 more
-
Jacksonville, Florida
- +5 more
Aug 14, 2023
Sickle Cell Disease Trial in United States (CD34 selected T-cell depleted allogeneic SCT)
Active, not recruiting
- Sickle Cell Disease
- CD34 selected T-cell depleted allogeneic SCT
-
Los Angeles, California
- +5 more
Sep 27, 2022